Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists

I read with interest, the recently published manuscript by Scailteux et al., investigating whether cardiovascular risks differ by the type of androgen deprivation therapy selected in men with newly treated prostate cancer [1]. The authors specifically cited our analysis (ref 14) which raised the hypothesis that Gonadotropin Releasing Hormone (GnRH) antagonists may lower cardiovascular risks when compared with agonists but neglected to test our full hypothesis that this difference occurs primarily in men with pre-existing cardiovascular disease [2].

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2foAbLH
via IFTTT